Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPS-1020
- Development stage
- Preclinical
- Lead developer
- LuxBiome
- Administration
- Oral
01
Overview
EPS-1020 (also known as 1020 EPS) is a probiotic-derived exopolysaccharide (EPS) obtained from the *Lactiplantibacillus plantarum* strain LB 1020 [1]. Developed by LuxBiome and Chung-Ang University, EPS-1020 is being investigated as a potential antiviral agent for the prevention and treatment of rotavirus infections [1]. In preclinical studies, EPS-1020 demonstrated broad-spectrum virucidal activity *in vitro* against multiple human, porcine, and bovine rotavirus strains [1]. In neonatal mouse models, oral administration of EPS-1020 alleviated rotavirus-induced symptoms such as diarrhea, reduced viral shedding, and protected against histological damage in the small intestine [1].
- Other names
- Lactiplantibacillus plantarum LB 1020 exopolysaccharideexopolysaccharide from Lactiplantibacillus plantarum LB 1020
Beyond the preview
Go deeper on EPS-1020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPS-1020.